A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies.

Trial Profile

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs E 7974 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 17 Nov 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 17 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Dec 2008 Status changed from recruiting to active, no longer recruiting, as reported on ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top